California’s BioMarin Pharmaceutical is to acquire Inozyme Pharma for $4 per share in an all-cash transaction for a total consideration of approximately $270 million.

Danish diabetes and weight loss juggernaut Novo Nordisk is to part ways with its chief executive Lars Fruergaard Jørgensen as ...

Chinese pharmaceutical group Jiangsu Hengrui Pharmaceuticals (SHE: 600276) is set to raise up to HK$9.89 billion ($1.27 ...

Telomir Pharmaceuticals (Nasdaq: TLO), a US age-reversal science-based biotech, has identified Telomir-Ag2 as a novel drug ...

US biopharma Biohaven has been told by the US Food and Drug Administration (FDA) that the agency is extending the PDUFA date ...

The US Food and Drug Administration (FDA) has approved Incyte’s (Nasdaq: INCY) Zynyz (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination ...

The Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of sonpiretigene isteparvovec for the treatment of ...

Neurocrine Biosciences, the American biotech, has unveiled new data showing its drug Crenessity (crinecerfont) may help ...

Chinese AI drug developer METiS Pharmaceuticals is preparing for a Hong Kong initial public offering that could raise up to $200 million, highlighting the ongoing surge of investment in artificial ...